VEA
AVIR icon

Virtus ETF Advisers’s Atea Pharmaceuticals AVIR Stock Holding History

Virtus ETF Advisers’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,183
Closed -$72.5K – 435
2023
Q3 		$72.5K Sell
24,183
-2,403
-9% -$8.18K 0.04% 376
2023
Q2 		$99.4K Buy
26,586
+3,638
+16% +$13.6K 0.06% 382
2023
Q1 		$76.9K Sell
22,948
-8,814
-28% -$35.8K 0.04% 390
2022
Q4 		$153K Buy
31,762
+16,102
+103% +$81.5K 0.08% 340
2022
Q3 		$89K Buy
15,660
+112
+0.7% +$857 0.04% 426
2022
Q2 		$110K Sell
15,548
-3,785
-20% -$25.8K 0.04% 407
2022
Q1 		$140K Sell
19,333
-1,148
-6% -$7.79K 0.06% 236
2021
Q4 		$183K Buy
20,481
+11,549
+129% +$180K 0.07% 239
2021
Q3 		$313K Sell
8,932
-463
-5% -$12.8K 0.14% 198
2021
Q2 		$202K Buy
+9,395
New +$282K 0.08% 338

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus ETF Advisers's AVIR Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 24,183 shares — an estimated $72.5K sold.

Virtus ETF Advisers first reported a position in AVIR in Q2 2021 and held it in 10 quarters. The position peaked at $313K in Q3 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 24,183 Atea Pharmaceuticals shares in Q4 2023, an estimated $72.5K.
  • Virtus ETF Advisers first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Virtus ETF Advisers's Atea Pharmaceuticals position peaked at $313K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.